ConvaTec Group PLC

ConvaTec Group PLC

CTEC · LSE · Healthcare / Medical Instruments & Supplies

258.20GBX+2.40 (+0.94%)

Price History

Full chart

Market Stats

Previous Close255.80
Open256.20
Day Range255.40 – 258.60
52-Week Range191.68 – 253.86
Volume4.94M
Market Cap4.15B
P/E (TTM)43.32
Forward P/E12.97
EPS0.05
Dividend Yield2.56%
Beta0.77
50-Day Avg224.00
200-Day Avg222.99

About

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Jonathan Peter Mason
  • Employees10.00K
  • Headquarters20 Eastbourne Terrace, London, United Kingdom, W2 6LG, UK
  • Websitehttps://www.convatecgroup.com

Leadership

  • Mr. Jonathan Peter MasonCEO & Director · b. 1964
  • Ms. Fiona Victoria RyderChief Financial Officer & Director · b. 1975
  • Mr. Peter JarvisChief Operations Officer
  • Mr. Dave UbachsChief Digital & Information Officer
  • Mr. James Edward Spencer KertonEVP, General Counsel & Company Secretary · b. 1980
  • Ms. Emma RoseEVP & Chief People Officer
  • Ms. Kjersti Grimsrud Biotechnology, M.Sc.President & COO of Infusion Care · b. 1961
  • Mr. David ShepherdChief Commercial Officer
  • Ms. Evelyn Douglas J.D.EVP and Chief Strategy & Business Development Officer
  • Mr. Bruno PinheiroPresident & COO of Ostomy Care

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70B1.73B1.65B1.69B1.76B1.83B1.83B1.89B2.04B2.07B2.14B2.29B2.49B
Growth (%)-+1.95%-4.82%+2.30%+4.52%+3.83%-0.27%+3.67%+7.60%+1.68%+3.37%+6.85%+8.78%
Cost of Revenue753.50M820.20M797.40M778.40M812.70M855.00M871.60M874.20M914.50M955.10M938.20M1.01B1.12B
Gross Profit947.20M913.70M853.00M909.90M951.90M977.10M955.60M1.02B1.12B1.12B1.20B1.28B1.37B
Gross Margin55.69%52.70%51.68%53.89%53.94%53.33%52.30%53.85%55.13%53.92%56.21%56.07%55.19%
Operating Expense602.30M615.70M599.00M706.20M670.80M696.30M741.20M809.10M920.20M910.10M941.50M958.70M958.70M
Operating Income344.90M298.00M254.00M203.70M281.10M280.80M214.40M211.00M203.60M207.30M262.70M324.90M415.54M
Operating Margin20.28%17.19%15.39%12.07%15.93%15.33%11.73%11.14%9.99%10.00%12.26%14.19%16.69%
EBITDA532.50M483.00M427.90M367.70M451.90M461.50M424.20M390.70M405.40M419.10M455.50M540.20M644.24M
EBITDA Margin31.31%27.86%25.93%21.78%25.61%25.19%23.22%20.63%19.89%20.22%21.26%23.60%25.87%
Net Income-173.70M-286.50M-93.40M-202.80M158.40M221.60M9.80M112.50M117.60M62.90M130.30M190.50M178.67M
Net Income Margin-10.21%-16.52%-5.66%-12.01%8.98%12.10%0.54%5.94%5.77%3.03%6.08%8.32%7.18%
R&D32.00M37.20M55.50M53.00M57.80M49.90M54.80M82.40M94.50M93.10M110.00M111.70M115.37M
R&D as % of Total Revenue1.88%2.15%3.36%3.14%3.28%2.72%3.00%4.35%4.64%4.49%5.13%4.88%4.63%
Interest Expense261.90M294.90M303.60M271.40M58.40M65.20M73.60M44.10M36.20M49.10M73.30M73.50M71.47M
Interest Expense % of Total Revenue15.40%17.01%18.40%16.08%3.31%3.56%4.03%2.33%1.78%2.37%3.42%3.21%2.87%

Balance Sheet

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.73B4.23B4.07B4.50B4.56B3.96B3.79B3.51B3.80B3.66B3.61B3.77B3.67B3.59B3.71B3.52B3.78B
Total Liabilities5.68B5.65B5.74B6.35B6.69B6.14B4.01B2.27B2.28B2.04B2.05B2.10B1.98B1.98B2.02B1.83B2.26B
Total Equity-----2.13B-2.17B-218.80M1.25B1.52B1.62B1.56B1.67B1.69B1.61B1.69B1.69B1.52B
Cash102.50M69.20M81.50M129.40M271.40M234.00M273.00M264.10M289.30M315.60M385.80M565.40M463.40M143.80M97.60M64.70M75.03M
Total Debt----3.80B3.58B3.50B1.78B1.82B1.64B1.57B1.55B1.44B1.30B1.31B1.20B1.52B
Net Debt----3.52B3.34B3.23B1.51B1.53B1.33B1.19B983.10M971.70M1.16B1.21B1.14B1.45B

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow229.10M147.30M100.30M74.90M306.60M352.00M401.80M399.50M305.90M281.70M367.40M396.20M479.86M
Investing Cash Flow-33.80M-88.20M-36.90M-63.70M-182.60M-80.90M-72.80M-56.30M-206.50M-348.30M-285.70M-160.80M-212.36M
Financing Cash Flow-53.00M-73.60M-8.30M4.50M-119.30M-229.40M-252.50M-162.10M-199.90M-237.10M-124.00M-263.80M-263.41M
Capital Expenditure36.90M44.70M36.70M66.50M82.70M72.10M61.40M86.20M94.10M144.20M129.20M122.10M137.83M
Free Cash Flow192.20M102.60M63.60M8.40M223.90M279.90M340.40M313.30M211.80M137.50M238.20M274.10M342.03M
Dividends Paid869.20M26.30M26.30M26.30M26.30M74.90M79.90M62.90M85.80M88.10M110.70M130.20M142.94M
FCF to OCF83.89%69.65%63.41%11.21%73.03%79.52%84.72%78.42%69.24%48.81%64.83%69.18%71.28%
Dividend Paid to FCF452.24%25.63%41.35%313.10%11.75%26.76%23.47%20.08%40.51%64.07%46.47%47.50%41.79%

Earnings

Report DateOct 31, 2016Mar 2, 2017Aug 3, 2017Feb 15, 2018Aug 2, 2018Feb 14, 2019Aug 1, 2019Feb 28, 2020Aug 6, 2020Mar 5, 2021Apr 29, 2021Jul 30, 2021Oct 29, 2021Mar 8, 2022May 12, 2022Aug 4, 2022Nov 10, 2022Mar 9, 2023May 18, 2023Aug 2, 2023Nov 14, 2023Mar 6, 2024Feb 26, 2025May 22, 2025Jul 29, 2025Feb 23, 2027
EPS Estimate0.000.050.080.100.070.080.050.080.050.060.000.050.000.050.000.070.000.060.000.060.000.070.090.000.08-
EPS Actual-0.04-0.160.040.070.050.070.050.050.050.040.000.050.000.050.000.000.000.000.000.000.000.000.080.000.08-
Surprise--420.00%-50.00%-30.00%-28.57%-12.50%0.00%-37.50%0.00%-33.33%-0.00%-0.00%--100.00%--100.00%--100.00%--100.00%-1.86%-0.00%-
Timing-------------Pre-market-Pre-market-Pre-market-Pre-market----After-hoursPre-market

Key Statistics & Ratios

Market Cap4.15B
Enterprise Value5.36B
Trailing P/E43.32
Forward P/E12.97
PEG Ratio0.53
Price / Sales1.67
Price / Book3.85
EPS0.05
Book Value0.5511
Revenue (TTM)2.49B
Gross Profit (TTM)1.40B
EBITDA582.00M
Profit Margin4.98%
Operating Margin14.45%
Return on Equity7.65%
Return on Assets6.72%
Shares Outstanding1.92B
Shares Float1.95B
Beta0.77
Dividend Yield2.56%
Dividend Rate0.06
Payout Ratio116.90%

Dividends

20262×
0.02Aug 20, 20260.04Apr 16, 2026
20252×
0.01Aug 21, 20250.04Apr 17, 2025
20242×
0.01Aug 22, 20240.04Apr 25, 2024
20232×
0.01Aug 17, 20230.04Apr 6, 2023
20222×
0.01Aug 25, 20220.03Mar 31, 2022
20212×
0.01Sep 2, 20210.03Apr 1, 2021
20202×
0.01Sep 3, 20200.03Apr 2, 2020
20192×
0.01Sep 5, 20190.03Apr 4, 2019
20182×
0.01Sep 6, 20180.03Apr 5, 2018
20171×
0.01Sep 7, 2017